Impact News +++ Corporate News: Heidelberg Pharma AG (EQS) +++ HEIDELBERG PHARMA Aktie -5,66%

IGC PHARMA Aktie

>IGC PHARMA Aktienkurs

0.294 EUR +1.4% (Tradegate)

Ask: 0.294 EUR / 6803 Stück

Bid: 0.28 EUR / 7154 Stück

Tagesumsatz: 1258 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

IGC PHARMA Aktie über LYNX handeln

Intraday

1 Jahr

>IGC PHARMA Performance

1 Woche: +13,7%

1 Monat: -3,6%

3 Monate: -17,5%

6 Monate: +14,2%

1 Jahr: -14,9%

laufendes Jahr: -15,3%

>IGC PHARMA Aktie

Name:

IGC PHARMA INC. DL -,01

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US45408X3089 / A1T87A

Symbol/ Ticker:

IGS1 (Frankfurt)

Kürzel:

FRA:IGS1, ETR:IGS1, IGS1:GR

Index:

Webseite:

https://igcpharma.com/

Profil:

IGC Pharma Inc. is a pharmaceutical and biotechnol..
>Volltext..

Marktkapitalisierung:

25.94 Mio. EUR

Unternehmenswert:

25.1 Mio. EUR

Umsatz:

0.94 Mio. EUR

EBITDA:

-6.42 Mio. EUR

Nettogewinn:

-5.49 Mio. EUR

Gewinn je Aktie:

-0.07 EUR

Schulden:

0.13 Mio. EUR

Liquide Mittel:

0.94 Mio. EUR

Operativer Cashflow:

-4.72 Mio. EUR

Bargeldquote:

0.75

Umsatzwachstum:

-11.29%

Gewinnwachstum:

51.34%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

IGC PHARMA

Letzte Datenerhebung:

17.12.25

>IGC PHARMA Kennzahlen

Aktien/ Unternehmen:

Aktien: 92.87 Mio. St.

Frei handelbar: 77%

Leerverk. Aktien: -

Rückkaufquote: -16.79%

Mitarbeiter: 70

Umsatz/Mitarb.: 0.02 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 1002.44%

Bewertung:

KGV: -

KGV lG: -

KUV: 27.84

KBV: 4.03

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 0.18%

Gewinnmarge: -582.82%

Operative Marge: -731.83%

Managementeffizenz:

Gesamtkaprendite: -64.1%

Eigenkaprendite: -83.34%

>IGC PHARMA Peer Group

Es sind 599 Aktien bekannt.

>IGC PHARMA Chart & Kurs - Tradegate

>IGC PHARMA News

25.11.25 - 15:06	IGC Pharma, Inc.: IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer′s and Aging Trends (Accesswire)
	POTOMAC, MD / ACCESS Newswire / November 25, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop inn......

17.11.25 - 18:06	Earnings Call zu Q2 2025: IGC Pharma meldet Fortschritte bei Alzheimer-Studie (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

17.11.25 - 14:48	IGC Pharma GAAP EPS of -$0.02 in-line, revenue of $0.19M misses by $0.13M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

17.11.25 - 14:42	IGC Pharma, Inc.: IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital (Accesswire)
	Company Accelerates Phase 2 Alzheimer's Program and Gains National Institute on Aging (NIA) Recognition for AI Leadership POTOMAC, MARYLAND / ACCESS Newswire / November 17, 2025 / IGC Pharma, Inc. ......

15.11.25 - 01:00	IGC Pharma, Inc. (IGC) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
	IGC Pharma, Inc. (IGC) delivered earnings and revenue surprises of 0.00% and -56.59%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?...

07.11.25 - 18:54	Earnings Call Q4 2025: IGC Pharma legt Fokus auf Alzheimer-Studien (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

24.10.25 - 19:45	All You Need to Know About IGC Pharma, Inc. (IGC) Rating Upgrade to Strong Buy (Zacks)
	IGC Pharma, Inc. (IGC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

11.10.25 - 02:06	IGC Pharma, Inc.: IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders (Accesswire)
	POTOMAC, MARYLAND / ACCESS Newswire / October 10, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develo......

07.10.25 - 15:06	IGC Pharma, Inc.: IGC Pharma′s Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer′s Disease (Accesswire)
	IGC-1C Targets Tau Protein's Liquid-Liquid Phase Separation (LLPS), Posing a Novel Threat to Neurotoxic Tangles; High Binding Affinity Confirmed POTOMAC, MD / ACCESS Newswire / October 7, 2025 / IG......

22.09.25 - 15:06	IGC Pharma, Inc.: IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer′s Agitation Trial (Accesswire)
	POTOMAC, MD / ACCESS Newswire / September 22, 2025 / IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage pharmaceutical company focused on therapies for Alzheimer's disease, today announced it h......

02.09.25 - 15:06	IGC Pharma, Inc.: IGC Pharma Expands CALMA Phase 2 Trial to Island Health′s Royal Jubilee Hospital in Canada (Accesswire)
	POTOMAC, MD / ACCESS Newswire / September 2, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced expansion of its ongoing Phase 2 clinical trial evaluating IGC-AD1, a novel investigational ......

28.08.25 - 15:06	IGC Pharma, Inc.: IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette′s Syndrome (Accesswire)
	POTOMAC, MD / ACCESS Newswire / August 28, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USP......

25.08.25 - 15:06	IGC Pharma, Inc.: IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City (Accesswire)
	POTOMAC, MD / ACCESS Newswire / August 25, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced the expansion of its ongoing Phase 2 clinical trial evaluating IGC-AD1, an investigational dru......

19.08.25 - 15:27	IGC Pharma GAAP EPS of -$0.02 beats by $0.01, revenue of $0.33M misses by $0.16M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

15.08.25 - 01:00	IGC Pharma, Inc. (IGC) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
	IGC Pharma, Inc. (IGC) delivered earnings and revenue surprises of +33.33% and -0.61%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?...

21.07.25 - 15:06	IGC Pharma, Inc.: IGC Pharma′s Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards (Accesswire)
	POTOMAC, MD / ACCESS Newswire / July 21, 2025 / IGC Pharma, Inc. (NYSE American:IGC) a clinical-stage biopharmaceutical company focused on Alzheimer's disease, today announced that its Principal Sc......

10.07.25 - 21:21	IGC Pharma, Inc.: IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer′s Risk and Accelerate Early Detection (Accesswire)
	- Multimodal foundation model enables personalized cognitive forecasts and expands access to Alzheimer's diagnostics - POTOMAC, MD / ACCESS Newswire / July 10, 2025 / IGC Pharma, Inc. (NYSE America......

10.07.25 - 06:48	Massive 69.4% Surge for IGC Pharma in After-Hours Trading: Heres Why (Benzinga)
	Rebounding from a recent dip to $0.32, IGC Pharma's stock surged 69.4% to $0.62 on Wednesday, in after-hours trading. read more...

30.06.25 - 18:00	IGC Pharma GAAP EPS of -$0.09 beats by $0.02, revenue of $1.2M misses by $0.25M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

30.06.25 - 15:06	IGC Pharma, Inc.: IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer′s Innovation (Accesswire)
	POTOMAC, MARYLAND / ACCESS Newswire / June 30, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging AI to develop innovative treat......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Der Mensch ward zum Tun und nicht zum Vernünfteln erschaffen. Aber eben deswegen, weil er nicht dazu erschaffen ward, hängt er diesem mehr als jenem nach. - Gotthold Ephraim Lessing

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram